BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25430799)

  • 1. Genetic features of Lynch syndrome in the Israeli population.
    Goldberg Y; Barnes-Kedar I; Lerer I; Halpern N; Plesser M; Hubert A; Kadouri L; Goldshmidt H; Solar I; Strul H; Rosner G; Baris HN; Peretz T; Levi Z; Kariv R
    Clin Genet; 2015 Jun; 87(6):549-53. PubMed ID: 25430799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mismatch repair genes founder mutations and cancer susceptibility in Lynch syndrome.
    Ponti G; Castellsagué E; Ruini C; Percesepe A; Tomasi A
    Clin Genet; 2015 Jun; 87(6):507-16. PubMed ID: 25345868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lynch Syndrome in high risk Ashkenazi Jews in Israel.
    Goldberg Y; Kedar I; Kariiv R; Halpern N; Plesser M; Hubert A; Kaduri L; Sagi M; Lerer I; Abeliovich D; Hamburger T; Nissan A; Goldshmidt H; Solar I; Geva R; Strul H; Rosner G; Baris H; Levi Z; Peretz T
    Fam Cancer; 2014 Mar; 13(1):65-73. PubMed ID: 23990280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Lynch syndrome in consecutive patients with colorectal cancer.
    Green RC; Parfrey PS; Woods MO; Younghusband HB
    J Natl Cancer Inst; 2009 Mar; 101(5):331-40. PubMed ID: 19244167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High frequency of exon deletions and putative founder effects in French Canadian Lynch syndrome families.
    Chong G; Jarry J; Marcus V; Thiffault I; Winocour S; Monczak Y; Drouin R; Latreille J; Australie K; Bapat B; Gordon PH; Giguère Y; Gologan A; Galiatsatos P; Jass JR; Wong N; Zaor S; Palma L; Kasprzak L; Tischkowitz M; Foulkes WD
    Hum Mutat; 2009 Aug; 30(8):E797-812. PubMed ID: 19459153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of new founder Alu-mediated rearrangements in MSH2 gene associated with a Lynch syndrome phenotype.
    Pérez-Cabornero L; Borrás Flores E; Infante Sanz M; Velasco Sampedro E; Acedo Becares A; Lastra Aras E; Cuevas González J; Pineda Riu M; Ramón y Cajal Asensio T; Capellá Munar G; Miner Pino C; Durán Domínguez M
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1546-55. PubMed ID: 21778331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America.
    Rossi BM; Palmero EI; López-Kostner F; Sarroca C; Vaccaro CA; Spirandelli F; Ashton-Prolla P; Rodriguez Y; de Campos Reis Galvão H; Reis RM; Escremim de Paula A; Capochin Romagnolo LG; Alvarez K; Della Valle A; Neffa F; Kalfayan PG; Spirandelli E; Chialina S; Gutiérrez Angulo M; Castro-Mujica MDC; Sanchez de Monte J; Quispe R; da Silva SD; Rossi NT; Barletta-Carrillo C; Revollo S; Taborga X; Morillas LL; Tubeuf H; Monteiro-Santos EM; Piñero TA; Dominguez-Barrera C; Wernhoff P; Martins A; Hovig E; Møller P; Dominguez-Valentin M
    BMC Cancer; 2017 Sep; 17(1):623. PubMed ID: 28874130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC.
    Goldberg Y; Porat RM; Kedar I; Shochat C; Galinsky D; Hamburger T; Hubert A; Strul H; Kariiv R; Ben-Avi L; Savion M; Pikarsky E; Abeliovich D; Bercovich D; Lerer I; Peretz T
    Fam Cancer; 2010 Jun; 9(2):141-50. PubMed ID: 19851887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A population-based study of hereditary non-polyposis colorectal cancer: evidence of pathologic and genetic heterogeneity.
    Warden G; Harnett D; Green J; Wish T; Woods MO; Green R; Dicks E; Rahman P; Zhai G; Parfrey P
    Clin Genet; 2013 Dec; 84(6):522-30. PubMed ID: 23278430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a novel founder MSH6 mutation causing Lynch syndrome in the French Canadian population.
    Castellsagué E; Liu J; Volenik A; Giroux S; Gagné R; Maranda B; Roussel-Jobin A; Latreille J; Laframboise R; Palma L; Kasprzak L; Marcus VA; Breguet M; Nolet S; El-Haffaf Z; Australie K; Gologan A; Aleynikova O; Oros-Klein K; Greenwood C; Mes-Masson AM; Provencher D; Tischkowitz M; Chong G; Rousseau F; Foulkes WD
    Clin Genet; 2015 Jun; 87(6):536-42. PubMed ID: 25318681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haplotype analysis suggest that the MLH1 c.2059C > T mutation is a Swedish founder mutation.
    von Salomé J; Liu T; Keihäs M; Morak M; Holinski-Feder E; Berry IR; Moilanen JS; Baert-Desurmont S; Lindblom A; Lagerstedt-Robinson K
    Fam Cancer; 2018 Oct; 17(4):531-537. PubMed ID: 29288294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in the diagnosis and management of Lynch Syndrome in an Indigenous family living in a remote West Australian community.
    Schofield L; Goldblatt J; Iacopetta B
    Rural Remote Health; 2011; 11(4):1836. PubMed ID: 22188021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New founding mutation in MSH2 associated with hereditary nonpolyposis colorectal cancer syndrome on the Island of Tenerife.
    Medina-Arana V; Barrios Y; Fernández-Peralta A; Herrera M; Chinea N; Lorenzo N; Jiménez A; Martín-López JV; González-Hermoso F; Salido E; González-Aguilera JJ
    Cancer Lett; 2006 Dec; 244(2):268-73. PubMed ID: 16500024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lynch syndrome: a pediatric perspective.
    Huang SC; Durno CA; Erdman SH
    J Pediatr Gastroenterol Nutr; 2014 Feb; 58(2):144-52. PubMed ID: 24051481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic anticipation in Swedish Lynch syndrome families.
    von Salomé J; Boonstra PS; Karimi M; Silander G; Stenmark-Askmalm M; Gebre-Medhin S; Aravidis C; Nilbert M; Lindblom A; Lagerstedt-Robinson K
    PLoS Genet; 2017 Oct; 13(10):e1007012. PubMed ID: 29088233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium "Care for CMMR-D" (C4CMMR-D).
    Vasen HF; Ghorbanoghli Z; Bourdeaut F; Cabaret O; Caron O; Duval A; Entz-Werle N; Goldberg Y; Ilencikova D; Kratz CP; Lavoine N; Loeffen J; Menko FH; Muleris M; Sebille G; Colas C; Burkhardt B; Brugieres L; Wimmer K;
    J Med Genet; 2014 May; 51(5):283-93. PubMed ID: 24556086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Founder effect of a pathogenic MSH2 mutation identified in Spanish families with Lynch syndrome.
    Menéndez M; Castellví-Bel S; Pineda M; de Cid R; Muñoz J; González S; Teulé A; Balaguer F; Ramón y Cajal T; Reñé JM; Blanco I; Castells A; Capellà G
    Clin Genet; 2010 Aug; 78(2):186-90. PubMed ID: 20095990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lynch Syndrome/Hereditary Non-polyposis Colorectal Cancer (HNPCC).
    Stoffel EM
    Minerva Gastroenterol Dietol; 2010 Mar; 56(1):45-53. PubMed ID: 20190724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frameshift mutational target gene analysis identifies similarities and differences in constitutional mismatch repair-deficiency and Lynch syndrome.
    Maletzki C; Huehns M; Bauer I; Ripperger T; Mork MM; Vilar E; Klöcking S; Zettl H; Prall F; Linnebacher M
    Mol Carcinog; 2017 Jul; 56(7):1753-1764. PubMed ID: 28218421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two Swedish founder MSH6 mutations, one nonsense and one missense, conferring high cumulative risk of Lynch syndrome.
    Cederquist K; Emanuelsson M; Wiklund F; Golovleva I; Palmqvist R; Grönberg H
    Clin Genet; 2005 Dec; 68(6):533-41. PubMed ID: 16283884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.